Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Matinas BioPharma Holdings, Inc.v469602_ex99-1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  June 26, 2017

 

MATINAS BIOPHARMA HOLDINGS, INC.
(Exact name of registrant as specified in its charter)

 

Delaware 001-38022 46-3011414
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

1545 Route 206 South, Suite 302

Bedminster, New Jersey

07921
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (908) 443-1860

 

Not Applicable
(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

x

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On June 26, 2017, Matinas BioPharma Holdings, Inc. (the “Company”) issued a press release to report topline data from its Phase 2 safety, tolerability and efficacy study of MAT2203 in women with moderate to severe vulvovaginal candidiasis (“VVC”). The press release is attached hereto as Exhibit 99.1.

  

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01Financial Statements and Exhibits.

 

(d)   Exhibit No.   Description.
    99.1   Press Release, dated June 26, 2017.  

 

 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

                                                                                     

  MATINAS BIOPHARMA HOLDINGS, INC.
     
Dated:  June 26, 2017 By: /s/ Roelof Rongen
    Name: Roelof Rongen
    Title: Chief Executive Officer